The advent in metabolomic techniques and supporting bioinformatic tools opened new perspectives in several areas of human health such as identification of metabolites affected by diet or lifestyle, as well as identification of metabolites specific for a variety of diseases such as cancer, neurodegenerative diseases, gastrointestinal diseases, metabolic disorders, inflammatory and many other diseases. Moreover, metabolic approaches allowed not only to identify but, in a number of cases, to define a set of metabolic markers for early detection of disease, when the clinical signs are yet to be manifested. Early detection allows earlier therapeutic intervention thus minimising disease consequences.
The recent developments in metabolomics techniques mentioned above are characterised by high-throughput, smaller sample size, higher sensitivity, broader coverage of metabolites, faster analysis, decreased cost, miniaturisation, and automation. The bioinformatics part of metabolomics is geared towards the development of freely available open-source software and public databases, standardisation of data reports for data sharing and analysis, and the development of software platforms providing the complete workflow for large amounts of data.
These developments had a profound effect on the strategy and implementation of antimicrobial drug discovery. Metabolomics-enabled and mechanism-based approach in antimicrobial drug discovery allows to broaden the sampling base and assess the ecological niches that previously, with the use of activity-based methods, were difficult to analyse. Besides, high-throughput automated metabolomic approach provides fast dereplication of antimicrobials from natural and synthetic sources, thus expediting antimicrobial drug discovery process and potentially identifying compounds with novel mechanisms of action. Mechanism-based metabolomics approach allows identifying non-antimicrobial compounds that affect bacterial metabolism and thus could be a basis for combination therapy. The link between the bacterial metabolome and virulence could be exploited to modulate virulence via metabolome and thus limit damage to the host. Metabolomics approach also plays an important role in identification of antimicrobial mode of action, drug-target characterisation, drug-drug interaction, and drug repurposing.
The aim of this Research Topic is to gather the recent developments in metabolomic approaches geared towards the discovery and development of antimicrobial drugs. Submissions can be made in all acceptable formats.
The advent in metabolomic techniques and supporting bioinformatic tools opened new perspectives in several areas of human health such as identification of metabolites affected by diet or lifestyle, as well as identification of metabolites specific for a variety of diseases such as cancer, neurodegenerative diseases, gastrointestinal diseases, metabolic disorders, inflammatory and many other diseases. Moreover, metabolic approaches allowed not only to identify but, in a number of cases, to define a set of metabolic markers for early detection of disease, when the clinical signs are yet to be manifested. Early detection allows earlier therapeutic intervention thus minimising disease consequences.
The recent developments in metabolomics techniques mentioned above are characterised by high-throughput, smaller sample size, higher sensitivity, broader coverage of metabolites, faster analysis, decreased cost, miniaturisation, and automation. The bioinformatics part of metabolomics is geared towards the development of freely available open-source software and public databases, standardisation of data reports for data sharing and analysis, and the development of software platforms providing the complete workflow for large amounts of data.
These developments had a profound effect on the strategy and implementation of antimicrobial drug discovery. Metabolomics-enabled and mechanism-based approach in antimicrobial drug discovery allows to broaden the sampling base and assess the ecological niches that previously, with the use of activity-based methods, were difficult to analyse. Besides, high-throughput automated metabolomic approach provides fast dereplication of antimicrobials from natural and synthetic sources, thus expediting antimicrobial drug discovery process and potentially identifying compounds with novel mechanisms of action. Mechanism-based metabolomics approach allows identifying non-antimicrobial compounds that affect bacterial metabolism and thus could be a basis for combination therapy. The link between the bacterial metabolome and virulence could be exploited to modulate virulence via metabolome and thus limit damage to the host. Metabolomics approach also plays an important role in identification of antimicrobial mode of action, drug-target characterisation, drug-drug interaction, and drug repurposing.
The aim of this Research Topic is to gather the recent developments in metabolomic approaches geared towards the discovery and development of antimicrobial drugs. Submissions can be made in all acceptable formats.
